BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33664813)

  • 1. Use of four genes in exosomes as biomarkers for the identification of lung adenocarcinoma and lung squamous cell carcinoma.
    Cao B; Wang P; Gu L; Liu J
    Oncol Lett; 2021 Apr; 21(4):249. PubMed ID: 33664813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Identification of differentially expressed genes between lung adenocarcinoma and squamous cell carcinoma using transcriber signature analysis].
    Peng S; Li X; Liu Q; Zhang Y; Zou L; Gong X; Wang M; Ma X
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jun; 39(6):641-649. PubMed ID: 31270041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Profiling of Genomic and Transcriptomic Differences between Risk Groups of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Zengin T; Önal-Süzek T
    J Pers Med; 2021 Feb; 11(2):. PubMed ID: 33672117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desmoglein 3 and Keratin 14 for Distinguishing Between Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Dong Y; Li S; Sun X; Wang Y; Lu T; Wo Y; Leng X; Kong D; Jiao W
    Onco Targets Ther; 2020; 13():11111-11124. PubMed ID: 33149622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LINC00628 is differentially expressed between lung adenocarcinoma and squamous cell carcinoma and is associated with the prognosis of NSCLC.
    Liu T; Xu S; Liu X
    Oncol Lett; 2022 Feb; 23(2):55. PubMed ID: 34992687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of specific prognostic markers for lung squamous cell carcinoma based on tumor progression, immune infiltration, and stem index.
    Wu R; Ma R; Duan X; Zhang J; Li K; Yu L; Zhang M; Liu P; Wang C
    Front Immunol; 2023; 14():1236444. PubMed ID: 37841237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct Patterns of mRNA and lncRNA Expression Differences Between Lung Squamous Cell Carcinoma and Adenocarcinoma.
    Tian Y; Yu M; Sun L; Liu L; Wang J; Hui K; Nan Q; Nie X; Ren Y; Ren X
    J Comput Biol; 2020 Jul; 27(7):1067-1078. PubMed ID: 31750732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
    Yang Y; Wang M; Liu B
    J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
    Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
    Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioinformatics analysis of differentially expressed miRNAs in non-small cell lung cancer.
    Yu H; Pang Z; Li G; Gu T
    J Clin Lab Anal; 2021 Feb; 35(2):e23588. PubMed ID: 32965722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Wang J; Zhan X
    Front Immunol; 2021; 12():752643. PubMed ID: 34887858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrative bioinformatics analysis the clinical value of KMT5A in different subtypes of lung cancer.
    Liu S; Tian W; Li B
    Comput Biol Chem; 2022 Feb; 96():107603. PubMed ID: 34894606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma.
    Ning J; Jiang S; Li X; Wang Y; Deng X; Zhang Z; He L; Wang D; Jiang Y
    BMC Pulm Med; 2021 Jun; 21(1):199. PubMed ID: 34112123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioinformatics analyses of the differences between lung adenocarcinoma and squamous cell carcinoma using The Cancer Genome Atlas expression data.
    Sun F; Yang X; Jin Y; Chen L; Wang L; Shi M; Zhan C; Shi Y; Wang Q
    Mol Med Rep; 2017 Jul; 16(1):609-616. PubMed ID: 28560415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of the key genes and characterizations of Tumor Immune Microenvironment in Lung Adenocarcinoma (LUAD) and Lung Squamous Cell Carcinoma (LUSC).
    Zhang L; Chen J; Cheng T; Yang H; Li H; Pan C
    J Cancer; 2020; 11(17):4965-4979. PubMed ID: 32742444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. System analysis of
    Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomere-associated genes and telomeric lncRNAs are biomarker candidates in lung squamous cell carcinoma (LUSC).
    Storti CB; de Oliveira RA; de Carvalho M; Hasimoto EN; Cataneo DC; Cataneo AJM; De Faveri J; Vasconcelos EJR; Dos Reis PP; Cano MIN
    Exp Mol Pathol; 2020 Feb; 112():104354. PubMed ID: 31837325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Li Y; Zheng P; Zhan X
    Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically relevant immune subtypes based on alternative splicing landscape of immune-related genes for lung cancer advanced PPPM approach.
    Li N; Jia W; Wang J; Shao Q; Feng X; Li Z; Sun W; Kang M; Hu D; Xing L; Zhan X
    EPMA J; 2024 Jun; 15(2):345-373. PubMed ID: 38841624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC.
    Fu L; Wang H; Wei D; Wang B; Zhang C; Zhu T; Ma Z; Li Z; Wu Y; Yu G
    PLoS One; 2020; 15(5):e0233283. PubMed ID: 32437446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.